Cellenkos to test CK0801 for bone marrow failure syndromes treatment
Category: #health  By Mateen Dalal  Date: 2019-06-06
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Cellenkos to test CK0801 for bone marrow failure syndromes treatment

Cellenkos Inc., an early stage clinical biotechnology company recently announced initiation of Phase 1 clinical trial of CK0801 for treatment of bone marrow failure syndromes, including primary myelofibrosis, hypoplastic myelodysplasia & aplastic anemia, cites source.

For the record, bone marrow failure syndrome denotes a group of life-threatening diseases with malfunctioned production of white blood cells (that lead to severe infection), red blood cells (that leads to anemia) & platelets (that leads to bleeding). Uncontrolled inflammation, immune dysfunction & defective T-regulatory cells propagate bone marrow failure syndromes.

Bone marrow failure syndrome is indicated by disease-driving cytotoxic T-cells’ uncontrolled attacks leading to an inflammatory microenvironment & inhibited normal blood cell production in the bone marrow. CK0801 supplies healthy regulatory T-cells to suppress cytotoxic T-cells & bone marrow inflammation and aids normalization of blood cell production.

As per credible sources, CK0801 is developed from Cellenkos' patented manufacturing platform and is allogeneic, cord blood-derived T-regulatory cell product. It inhibits key drivers of inflammation to overcome immune dysfunction. It contains healthy regulatory T-cells that are derived from healthy donor’s cord blood units. CK0801 is manufactured at Cellenkos’ GMP manufacturing facility, Texas. In June 2018, first CK0801 was approved by USFDA.

Elizabeth J. Read, MD & Chief Technology Officer, Cellenkos was reportedly quoted saying that clinical trial of CK0801 for bone marrow failure syndromes is a significant event for Cellenkos. The company’s programs include advancement of cord blood-derived T-regulatory cells products which are used for treatment of hematologic diseases, neuro-inflammatory disorders, graft vs. host disease & autoimmune diseases. The company aims at validating the cellular product as safe & capable of providing clinical benefit to range of serious illnesses.

As per sources close to the matter, the clinical trial of CK0801 will be led by Tapan Kadi (MD, Assistant Professor of Leukemia at University of Texas MD Anderson Cancer Center, Texas).

Source credits: https://finance.yahoo.com/news/cellenkos-inc-initiates-phase-1-131700344.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Sony sells 10 million Play Station consoles just 294 days after launch

Sony sells 10 million Play Station consoles just 294 days after launch

By Mateen Dalal

Sony has reportedly managed to sell around 10 million Play Station 5 consoles in 249 days after its launch in November 2020. The company had sold approximately 7.8 million PS5 units as of April 2021. In comparison, approximately 10 million units of ...

Chevrolet Camaro could be replaced by a potential all-electric sedan

Chevrolet Camaro could be replaced by a potential all-electric sedan

By Mateen Dalal

Reportedly, General Motors Company is planning to replace the Chevrolet Camaro with an all-electric performance sedan in a few years with the existing model likely to be phased out by 2024. There have many reports about discontinuing the Camaro&rsqu...

Sequoia India launches Spark Fellowship to support female entrepreneurs

Sequoia India launches Spark Fellowship to support female entrepreneurs

By Mateen Dalal

The Spark fellowship program is for women entrepreneurs in India and Southeast Asia. The year-long program is aimed at bringing more gender diversity and supporting startups led by women. Sequoia Capital has recently revealed the launch of a yea...